HMGN — Hemagen Diagnostics Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -88.83% | ||
| Return on Equity | n/a | ||
| Operating Margin | -10.83% | ||
Financial Summary
| Year End 30th Sep | Unit | 2008 | 2009 | 2010 | 2011 | 2012 | 2013E | 2014E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 6.38 | 5.42 | 5.22 | 5.14 | 4.04 | n/a | n/a | -2.07% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Hemagen Diagnostics, Inc. is engaged in providing clinical diagnostic solutions. The Company is primarily focused on Veterinary Clinical Diagnostics. It is also focused on VIRGO, its Human Clinical Diagnostic line of autoimmune and infectious disease products. The Company develops, manufactures and markets a range of test kits used to aid in the diagnosis of certain autoimmune and infectious diseases. The Company’s autoimmune product portfolio includes Hemagen DNA Kit, Hemagen Rheumatoid Factor Kit, VIRGO AMA IgG, VIRGO ANA/Hep-2 IgG, VIRGO Anti-nDNA IgG, VIRGO cANCA (PR-3) Kit, VIRGO dsDNA Kit, VIRGO ENA Screen 6 Kit, VIRGO ENA Screening, VIRGO ENA Series, VIRGO pANCA myeloperoxidase (MPO) Kit and VIRGO Rheumatoid Factor Kit. It offers various products for infectious disease, which includes VIRGO C. trach IgG, VIRGO CMV IgG and VIRGO epstein-barr virus (EBV)- viral capsid antigen (VCA) IgG. Its products are used in laboratories, hospitals and blood banks around the world.
Directors
- William Hales CHM (50)
- M. Robert Campbell CFO (43)
- Catherine Davidson CAO (47)
- Alan Cohen IND (86)
- Edward Lutz IND (66)
- Last Annual
- September 30th, 2012
- Last Interim
- September 30th, 2012
- Incorporated
- May 1st, 1992
- Public Since
- February 4th, 1993
- No. of Shareholders
- 1,233
- No. of Employees
- 15
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 15,500,281
- Address
- 9033 Red Branch Rd, COLUMBIA, 21045-2396
- Web
- http://www.hemagen.com/
- Phone
- +1 4433675500
- Auditors
- Stegman & Company
Similar to HMGN
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
Aksys
Pink Sheets on Nasdaq
FAQ
As of Today at 19:10 UTC, shares in Hemagen Diagnostics are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Hemagen Diagnostics last closed at $0.00 and the price had moved by -99% over the past 365 days. In terms of relative price strength the Hemagen Diagnostics share price has underperformed the S&P500 Index by -99.12% over the past year.
There is no consensus recommendation for this security.
Hemagen Diagnostics does not currently pay a dividend.
Hemagen Diagnostics does not currently pay a dividend.
Hemagen Diagnostics does not currently pay a dividend.
To buy shares in Hemagen Diagnostics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Hemagen Diagnostics had a market capitalisation of .
Here are the trading details for Hemagen Diagnostics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: HMGN
Based on an overall assessment of its quality, value and momentum Hemagen Diagnostics is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hemagen Diagnostics. Over the past six months, its share price has underperformed the S&P500 Index by -99.14%.
As of the last closing price of $0.00, shares in Hemagen Diagnostics were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Hemagen Diagnostics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Hemagen Diagnostics' management team is headed by:
- William Hales - CHM
- M. Robert Campbell - CFO
- Catherine Davidson - CAO
- Alan Cohen - IND
- Edward Lutz - IND